Health-care companies rose amid deal activity.
Argenx acquired Forte for $2.2B to expand immunology; AstraZeneca confirmed 2030 targets with strong oncology Q2 sales. M&A consolidation in pharma signals tech stack investments flowing toward healthcare data and AI; relevant for enterprise cloud strategy decisions.
Health-care companies rose amid deal activity.
European pharmaceutical firm Argenx struck a deal to buy rival Forte Biosciences for $2.2 billion, bulking up its immunology portfolio.
U.K. drug giant AstraZeneca said it was on track to hit its revenue target for 2030 and has drugs in the pipeline to fuel growth beyond, as the company reported higher second-quarter sales driven by its cancer medicines.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
Health-care companies rose as deal activity in the sector intensified.
Health-care companies rose amid deal activity and demand for sectors less sensitive to inflation rates.
Health-care companies ticked down as deal activity offset fears about generic competition for one key category of drugs.
Stocks of healthcare companies were the top gainers Thursday amid M&A activity while investors seek less volatile options.
Stocks in the Healthcare sector rose as U.S. indexes mostly declined amid slow progress on Middle East negotiations.
Health-care companies ticked up as traders hedged their bets on the outlook for growth in the sector.
